Alnylam Reports Completion of Patient Enrollment in P-III APOLLO-B Study for Patisiran to Treat Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy

 Alnylam Reports Completion of Patient Enrollment in P-III APOLLO-B Study for Patisiran to Treat Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy

Alnylam Reports Completion of Patient Enrollment in P-III APOLLO-B Study for Patisiran to Treat Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy

Shots:

  • The company has completed the enrolment in the P-III APOLLO-B study to evaluate the efficacy & safety of patisiran vs PBO in a ratio (2:1) in 300 patients with ATTR amyloidosis with cardiomyopathy across 90 sites in 20+ countries. The results are expected in mid-2022
  • The 1EPs of the trial is the change from baseline in 6 min. walk test @12 mos. The 2EPs is to assess the efficacy on health-related QoL, mortality & cardiovascular events, cardiac biomarkers & manifestations of cardiac amyloid
  • Onpattro (Patisiran) is an RNAi therapeutic, approved in US, Canada & Japan for polyneuropathy of hATTR amyloidosis & in EU, Switzerland & Brazil for hATTR amyloidosis with Stage 1 or Stage 2 polyneuropathy

Click here to­ read full press release/ article | Ref: Businesswire | Image: Pharmaphorum

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post